Endothelin receptor antagonists restore morphine analgesia in morphine tolerant rats

Peptides

Volumn 24, Issue 4, 2003, Pages 553-561

  Bhalla, Shaifali ^a   Matwyshyn, George ^a   Gulati, Anil ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Analgesia; BMS182874 (5 (dimethylamino) N (3,4 dimethyl 5 isoxazolyd) 1 naphthalenesulfonamide); BQ123 (cyclo( d Trp d Asp Pro d Val Leu)); Central nervous system; Dependence; Endothelin; Morphine; Opiates; Rats; Tolerance

Indexed keywords

5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN A RECEPTOR ANTAGONIST; MORPHINE SULFATE;

ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; LATENT PERIOD; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; TAIL FLICK TEST;

EID: 0037967790     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(03)00110-4     Document Type: Article

References (43)

1. Allen R.M., Dykstra L.A. Attenuation of mu-opioid tolerance and cross-tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY235959 is related to tolerance and cross-tolerance magnitude. J. Pharmacol. Exp. Ther. 295:2000;1012-1021.
2. Allen R.M., Dykstra L.A. Role of morphine maintenance dose in the development of tolerance and its attenuation by an NMDA receptor antagonist. Psychopharmacology (Berl.). 148:2000;59-65.
3. Bhalla S., Matwyshyn G., Gulati A. Potentiation of morphine analgesia by BQ123, an endothelin antagonist. Peptides. 23:2002;1837-1845.
4. Bisaga A., Popik P. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug Alcohol Depend. 59:2000;1-15.
5. Bisaga A., Popik P., Bespalov A.Y., Danysz W. Therapeutic potential of NMDA receptor antagonists in the treatment of alcohol and substance use disorders. Expert Opin. Invest. Drugs. 9:2000;2233-2248.
6. Collin E., Cesselin F. Neurobiological mechanisms of opioid tolerance and dependence. Clin. Neuropharmacol. 14:1991;465-488.
7. Fairbanks C.A., Wilcox G.L. Spinal plasticity of acute opioid tolerance. J. Biomed. Sci. 7:2000;200-212.
8. Fundytus M.E., Ritchie J., Coderre T.J. Attenuation of morphine withdrawal symptoms by subtype-selective metabotropic glutamate receptor antagonists. Br. J. Pharmacol. 120:1997;1015-1020.
9. Gulati A., Bhargava H.N. Cerebral cortical 5-HT1 and 5-HT2 receptors of morphine tolerant-dependent rats. Neuropharmacology. 27:1988;1231-1237.
10. Gulati A., Bhargava H.N. Down-regulation of hypothalamic 5-HT1A receptors in morphine-abstinent rats. Eur. J. Pharmacol. 182:1990;253-259.
11. Gulati A., Rebello S., Kumar A. Role of sympathetic nervous system in cardiovascular effects of centrally administered endothelin-1 in rats. Am. J. Physiol. 273:1997;H1177-H1186.
12. Gulati A., Srimal R.C. Endothelin mechanisms in the central nervous system: a target for drug development. Drug Dev. Res. 26:1992;361-387.
13. Hickey K.A., Rubanyi G., Paul R.J., Highsmith R.F. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am. J. Physiol. 248:1985;C550-C556.
14. Himmelsbach Symposium: can the euphoric analgetic, and physical dependence effects of drugs be separated? IV. With reference to physical dependence. Fed. Proc. 2:1943;201-203.
15. Ihara M., Noguchi K., Saeki T., Fukuroda T., Tsuchida S., Kimura S.et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 50:1992;247-255.
16. Katz JL, Valentino RJ. Pharmacological and behavioral factors in opioid dependence in animals. In: Goldberg SR, Stolerman IP, editors. Behavioral analysis of drug dependence. Orlando: Academic Press; 1986. p. 287-327 [chapter 8].
17. Kivipelto L., Panula P. Central neuronal pathways containing FLFQPQRFamide-like (morphine-modulating) peptides in the rat brain. Neuroscience. 41:1991;137-148.
18. Kivipelto L., Panula P. Comparative distribution of neurons containing FLFQPQRFamide-like (morphine-modulating) peptide and related neuropeptides in the rat brain. Eur. J. Neurosci. 3:1991;175-185.
19. Kivipelto L., Panula P. Origin and distribution of neuropeptide-FF-like immunoreactivity in the spinal cord of rats. J. Comp. Neurol. 307:1991;107-119.
20. Koyuncuoglu H., Gungor M., Sagduyu H., Aricioglu F. Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats. Pharmacol. Biochem. Behav. 35:1990;829-832.
21. Kumar A., Shahani B.T., Gulati A. Modification of systemic and regional circulatory effects of intracerebroventricular administration of endothelin-1 by propranolol in anesthetized rats. Gen. Pharmacol. 27:1996;1025-1033.
22. MacCumber M.W., Ross C.A., Snyder S.H. Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proc. Natl. Acad. Sci. U.S.A. 87:1990;2359-2363.
23. Maldonado R, Stinus L, Koob GF. Neuropsychopharmacology of opiate dependence. In: Maldonado R, Stinus L, Koob GF, editors. Neurobiological mechanisms of opiate withdrawal. New York: Springer; 1996. p. 77-124 [chapter 5].
24. Marek P., Ben-Eliyahu S., Gold M., Liebeskind J.C. Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res. 547:1991;77-81.
25. Mayer D.J., Mao J., Holt J., Price D.D. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc. Natl. Acad. Sci. U.S.A. 96:1999;7731-7736.
26. Narita M., Funada M., Suzuki T. Regulations of opioid dependence by opioid receptor types. Pharmacol. Ther. 89:2001;1-15.
27. Popik P., Kozela E., Danysz W. Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice. Naunyn Schmiedebergs Arch. Pharmacol. 361:2000;425-432.
28. Quock C.P., Cheng J., Chan S.C., Way E.L. The abstinence syndrome in long-term, high-dosage narcotic addiction. Br. J. Addict. Alcohol Other Drugs. 63:1968;261-270.
29. Rasmussen K., Fuller R.W., Stockton M.E., Perry K.W., Swinford R.M., Ornstein P.L. NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur. J. Pharmacol. 197:1991;9-16.
30. Rasmussen K., Kendrick W.T., Kogan J.H., Aghajanian G.K. A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropsychopharmacology. 15:1996;497-505.
31. Remuzzi G., Perico N., Benigni A. New therapeutics that antagonize endothelin: promises and frustrations. Nat. Rev. Drug Discov. 1:2002;986-1001.
32. Reynolds E.E., Mok L.L., Kurokawa S. Phorbol ester dissociates endothelin-stimulated phosphoinositide hydrolysis and arachidonic acid release in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 160:1989;868-873.
33. Rothman R.B. A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse. 12:1992;129-138.
34. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K.et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 348:1990;732-735.
35. Stein P.D., Hunt J.T., Floyd D.M., Moreland S., Dickinson K.E., Mitchell C.et al. The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide. J. Med. Chem. 37:1994;329-331.
36. Trujillo K.A. Are NMDA receptors involved in opiate-induced neural and behavioral plasticity? A review of preclinical studies. Psychopharmacology (Berl.). 151:2000;121-141.
37. Trujillo K.A. Cellular and molecular mechanisms of opioid tolerance and dependence: progress and pitfalls. Pain Forum. 8:1999;29-33.
38. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 251:1991;85-87.
39. Vaccarino A.L., Kastin A.J. Endogenous opiates: 1999. Peptides. 21:2000;1975-2034.
40. Vaccarino A.L., Kastin A.J. Endogenous opiates: 2000. Peptides. 22:2001;2257-2328.
41. Van Ree J.M., Gerritis M.A.F.M., Vanderschuren L.J.M.J. Opioids, reward and addiction: an encounter of biology, psychology, and medicine. Pharmacol. Rev. 51:1999;342-396.
42. Williams J.T., Christie M.J., Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol. Rev. 81:2001;299-343.
43. Yanagisawa M., Kurihara H., Kimura S., Goto K., Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J. Hypertens. 6(Suppl.):1988;S188-S191.